Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Benjamin Rix Brooks, Erik P. Pioro, Danielle Beaulieu, Albert A. Taylor, Mark Schactman, Mike Keymer, Wendy Agnese, Johnna Perdrizet, Stephen Apple & David L. Ennist. (2022) Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis tool. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 23:1-2, pages 49-57.
Read now
Read now
Jeremy M. Shefner, Jinsy A. Andrews, Angela Genge, Carlayne Jackson, Noah Lechtzin, Timothy M. Miller, Bettina M. Cockroft, Lisa Meng, Jenny Wei, Andrew A. Wolff, Fady I. Malik, Cynthia Bodkin, Benjamin R. Brooks, James Caress, Annie Dionne, Dominic Fee, Stephen A. Goutman, Namita A. Goyal, Orla Hardiman, Ghazala Hayat, Terry Heiman-Patterson, Daragh Heitzman, Robert D. Henderson, Wendy Johnston, Chafic Karam, Matthew C. Kiernan, Stephen J. Kolb, Lawrence Korngut, Shafeeq Ladha, Genevieve Matte, Jesus S. Mora, Merrilee Needham, Bjorn Oskarsson, Gary L. Pattee, Erik P. Pioro, Michael Pulley, Dianna Quan, Kourosh Rezania, Kerri L. Schellenberg, David Schultz, Christen Shoesmith, Zachary Simmons, Jeffrey Statland, Shumaila Sultan, Andrea Swenson, Leonard H. Van Den Berg, Tuan Vu, Steve Vucic, Michael Weiss, Ashley Whyte-Rayson, James Wymer, Lorne Zinman & Stacy A. Rudnicki. (2021) A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 22:3-4, pages 287-299.
Read now
Read now
Jeremy M. Shefner, Merit E. Cudkowicz, Orla Hardiman, Bettina M. Cockroft, Jacqueline H. Lee, Fady I. Malik, Lisa Meng, Stacy A. Rudnicki, Andrew A. Wolff & Jinsy A. Andrews. (2019) A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20:7-8, pages 584-594.
Read now
Read now
Jinsy A. Andrews, Merit E. Cudkowicz, Orla Hardiman, Lisa Meng, Amy Bian, Jacqueline Lee, Andrew A. Wolff, Fady I. Malik & Jeremy M. Shefner. (2018) VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:3-4, pages 259-266.
Read now
Read now
Susana Pinto & Mamede de Carvalho. (2017) Comparison of slow and forced vital capacities on ability to predict survival in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:7-8, pages 528-533.
Read now
Read now
Articles from other publishers (26)
Nicholas J. Maragakis, Mamede de Carvalho & Michael D. Weiss. (2023)
Therapeutic targeting of
ALS
pathways: Refocusing an incomplete picture
. Annals of Clinical and Translational Neurology 10:11, pages 1948-1971.
Crossref
Crossref
Wout J. Claassen, Rianne J. Baelde, Ricardo A. Galli, Josine M. de Winter & Coen A. C. Ottenheijm. (2023) Small molecule drugs to improve sarcomere function in those with acquired and inherited myopathies. American Journal of Physiology-Cell Physiology 325:1, pages C60-C68.
Crossref
Crossref
Xiaoyan Li, Dwight D. Koeberl, Michael W. Lutz & Richard Bedlack. (2023) Clenbuterol Treatment Is Safe and Associated With Slowed Disease Progression in a Small Open-Label Trial in Patients With Amyotrophic Lateral Sclerosis. Journal of Clinical Neuromuscular Disease 24:4, pages 214-221.
Crossref
Crossref
Rubika Balendra, Richard W Orrell, Neil Pearce & Ammar Al-Chalabi. (2023) Disease-modifying pharmacological treatments for amyotrophic lateral sclerosis/motor neuron disease: an overview of intervention reviews. Cochrane Database of Systematic Reviews 2023:3.
Crossref
Crossref
Belgin Sever, Halilibrahim Ciftci, Hasan DeMirci, Hilal Sever, Firdevs Ocak, Burak Yulug, Hiroshi Tateishi, Takahisa Tateishi, Masami Otsuka, Mikako Fujita & Ayşe Nazlı Başak. (2022) Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences 23:5, pages 2400.
Crossref
Crossref
Scott E. Collibee, Gustave Bergnes, Chihyuan Chuang, Luke Ashcraft, Jeffrey Gardina, Marc Garard, Chris R. Jamison, Kevin Lu, Pu-Ping Lu, Alexander Muci, Antonio Romero, Ellen Valkevich, Wenyue Wang, Jeffrey Warrington, Bing Yao, Nickie Durham, James Hartman, Anna Marquez, Aaron Hinken, Julia Schaletzky, Donghong Xu, Darren T. Hwee, David Morgans, Fady I. Malik & Bradley P. Morgan. (2021) Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function. Journal of Medicinal Chemistry 64:20, pages 14930-14941.
Crossref
Crossref
Merit Cudkowicz, Angela Genge, Nicholas Maragakis, Susanne Petri, Leonard van den Berg, Valtteri V Aho, Toni Sarapohja, Mikko Kuoppamäki, Chris Garratt, Ammar Al-Chalabi, Matthew Kiernan, Susan Mathers, Robert Henderson, Merrilee Needham, David Schultz, Wolfgang Löscher, Nenad Mitrovic, Jakob Rath, Philip Van Damme, Jan L. De Bleecker, Stéphanie Delstanche, Wendy Johnston, Lorne Zinman, Colleen O'Connell, Genevieve Matte, Annie Dionne, Lawrence Korngut, John Turnbull, Hannu Laaksovirta, Manu Jokela, Tero Tapiola, Marie-Hélène Soriani, Philippe Couratier, William Camu, Philippe Corcia, Albert Ludolph, Julian Großkreutz, Thomas Meyer, Matthias Boentert, Berthold Schrank, Johannes Prudlo, Robert Untucht, Orla Hardiman, Gabriele Siciliano, Adriano Chio'Letizia Mazzini, Maurizio Inghilleri, Claudia Caponnetto, Gabriele Mora, Jesús S Mora Pardina, Eva Farrero Munoz, Juan F Vázquez Costa, Eduardo Aguera Morales, Luis Varona, Peter Andersen, Caroline Ingre, Rune Johansson, Aleksandar Radunovic, Carolyn Young, Suma Babu, Aziz Shaibani, Nathan Staff, Tuan Vu, Michael Rivner, Stephen Scelsa, Kumaraswamy Sivakumar, Waqar Waheed, Daragh Heitzman, Sandeep Rana, Gary Pattee, Senda Ajroud-Driss, Elham Bayat, Edward Kasarskis, Dale J Lange, Michael Elliott, Brent Harris, Kevin Felice, Michael T Pulley, Justin Kwan, Martin Brown, John Ravits, Matthew Burford, Chafic Karam, Timothy Miller, Jinsy Andrews, Todd Levine, Eduardo Locatelli, James Wymer, Richard Bedlack, Dominic Fee, Namita Goyal, Bjorn Oskarsson, Leo McCluskey, James Caress, Michael Weiss, Adam Quick, Mark Bromberg, David Lacomis, Stephen Goutman, Kourosh Rezania, Gaurav Guliani, Kimberly Goslin & Jonathan S Katz. (2021) Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet Neurology 20:10, pages 821-831.
Crossref
Crossref
Kristiana Salmon & Angela Genge. 2021. Spectrums of Amyotrophic Lateral Sclerosis. Spectrums of Amyotrophic Lateral Sclerosis
161
180
.
Stacy A. Rudnicki, Jinsy A. Andrews, Tina Duong, Bettina M. Cockroft, Fady I. Malik, Lisa Meng, Jenny Wei, Andrew A. Wolff, Angela Genge, Nicholas E. Johnson, Carolina Tesi-Rocha, Anne M. Connolly, Basil T. Darras, Kevin Felice, Richard S. Finkel, Perry B. Shieh, Jean K. Mah, Jeffrey Statland, Craig Campbell, Ali A. Habib, Nancy L. Kuntz, Maryam Oskoui & John W. Day. (2021) Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study. Neurotherapeutics 18:2, pages 1127-1136.
Crossref
Crossref
Monica X. Li, Pascal Mercier, James J. Hartman & Brian D. Sykes. (2021)
Structural Basis of
Tirasemtiv
Activation of Fast Skeletal Muscle
. Journal of Medicinal Chemistry 64:6, pages 3026-3034.
Crossref
Crossref
Danielle Beaulieu, Albert A. Taylor, Dustin Pierce, Jonavelle Cuerdo, Mark Schactman, Mike Keymer & David L. Ennist. 2021. Neurotherapeutics in the Era of Translational Medicine. Neurotherapeutics in the Era of Translational Medicine
333
366
.
Khulud Alsulami & Steven Marston. (2020) Small Molecules Acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases. International Journal of Molecular Sciences 21:24, pages 9599.
Crossref
Crossref
Heike J. Wobst, Korrie L. Mack, Dean G. Brown, Nicholas J. Brandon & James Shorter. (2020) The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future. Medicinal Research Reviews 40:4, pages 1352-1384.
Crossref
Crossref
Christina N. Fournier, Richard Bedlack, Colin Quinn, James Russell, Diane Beckwith, Kathleen H. Kaminski, William Tyor, Vicki Hertzberg, Virginia James, Meraida Polak & Jonathan D. Glass. (2020) Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS). JAMA Neurology 77:4, pages 480.
Crossref
Crossref
Tereza Filipi, Zuzana Hermanova, Jana Tureckova, Ondrej Vanatko & Miroslava Anderova. (2020) Glial Cells—The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment. Journal of Clinical Medicine 9:1, pages 261.
Crossref
Crossref
Ammar Al-ChalabiLeo M. A. HeunksZoltán Papp & Piero Pollesello. (2019) Potential of the Cardiovascular Drug Levosimendan in the Management of Amyotrophic Lateral Sclerosis: An Overview of a Working Hypothesis. Journal of Cardiovascular Pharmacology 74:5, pages 389-399.
Crossref
Crossref
Eun-Jeong Lee, Justin Kolb, Darren T. Hwee, Fady I. Malik & Henk L. Granzier. (2019) Functional Characterization of the Intact Diaphragm in a Nebulin-Based Nemaline Myopathy (NM) Model-Effects of the Fast Skeletal Muscle Troponin Activator tirasemtiv. International Journal of Molecular Sciences 20:20, pages 5008.
Crossref
Crossref
Ammar Al-Chalabi, Pamela Shaw, P Nigel Leigh, Leonard van den Berg, Orla Hardiman, Albert Ludolph, Valtteri V Aho, Toni Sarapohja & Mikko Kuoppamäki. (2019) Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial. Journal of Neurology, Neurosurgery & Psychiatry 90:10, pages 1165-1170.
Crossref
Crossref
Antonio Musarò, Gabriella Dobrowolny, Chiara Cambieri, Emanuela Onesti, Marco Ceccanti, Vittorio Frasca, Annalinda Pisano, Bruna Cerbelli, Elisa Lepore, Gabriele Ruffolo, Pierangelo Cifelli, Cristina Roseti, Carla Giordano, Maria Cristina Gori, Eleonora Palma & Maurizio Inghilleri. (2019) Neuromuscular magnetic stimulation counteracts muscle decline in ALS patients: results of a randomized, double-blind, controlled study. Scientific Reports 9:1.
Crossref
Crossref
Seward B. Rutkove. (2018) The final frontier: Primary muscle dysfunction in amyotrophic lateral sclerosis. Muscle & Nerve 59:2, pages 152-153.
Crossref
Crossref
Hyoung Moo Park. (2018) Current Status of Sarcopenia in Korea: A Focus on Korean Geripausal Women. Annals of Geriatric Medicine and Research 22:2, pages 52-61.
Crossref
Crossref
Jinsy A. Andrews, Timothy M. Miller, Vipin Vijayakumar, Randall Stoltz, Joyce K. James, Lisa Meng, Andrew A. Wolff & Fady I. Malik. (2018) CK-2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle & Nerve 57:5, pages 729-734.
Crossref
Crossref
James D. Berry, Albert A. Taylor, Danielle Beaulieu, Lisa Meng, Amy Bian, Jinsy Andrews, Mike Keymer, David L. Ennist & Bernard Ravina. (2018) Improved stratification of ALS clinical trials using predicted survival. Annals of Clinical and Translational Neurology 5:4, pages 474-485.
Crossref
Crossref
Loqman A. Mohamed, Shashirekha Markandaiah, Silvia Bonanno, Piera Pasinelli & Davide Trotti. (2017) Blood–Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies. The AAPS Journal 19:6, pages 1600-1614.
Crossref
Crossref
Dmitry Petrov, Colin Mansfield, Alain Moussy & Olivier Hermine. (2017) ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?. Frontiers in Aging Neuroscience 9.
Crossref
Crossref
Jeremy M. Shefner. (2016) Strength Testing in Motor Neuron Diseases. Neurotherapeutics 14:1, pages 154-160.
Crossref
Crossref